Literature DB >> 22947444

Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs.

P A Jacobson1, D Schladt, W S Oetting, R Leduc, W Guan, A J Matas, A Israni.   

Abstract

The number of older adults undergoing kidney transplantation has increased, yet little is known about calcineurin inhibitor (CNI) metabolism in this group. We studied CNI troughs and doses to determine if there were age-related differences in metabolism and dose requirements. We studied 348 young (18-34 years), 1831 middle (35-64 years) and 374 older (65-84 years) adult kidney transplant recipients enrolled in a seven-center prospective study. Troughs were obtained from each patient 2×/week in weeks 1-8 and 2×/month in months 3-6. A multivariable linear-mixed model examined the effect of age on log dose and weight normalized troughs. Older recipients had higher normalized tacrolimus troughs than middle or young age adults despite receiving doses a median of 1-2 mg/day lower. Age and CYP3A5*1 genotype had the largest effect on tacrolimus troughs. Older recipients also had higher normalized cyclosporine troughs than middle or young adults despite receiving median doses 100 mg/day lower. After normalization for dose and weight, CNI troughs were more than 50% higher in older adults than young adults. These data support age-related changes in CNI metabolism. Further studies are needed to determine optimal dosing of CNIs in the elderly. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947444      PMCID: PMC3513646          DOI: 10.1111/j.1600-6143.2012.04232.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  33 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Adverse drug reaction-related hospitalizations in persons aged 55 years and over: a population-based study in the Netherlands.

Authors:  Rikje Ruiter; Loes E Visser; Eline M Rodenburg; Gianluca Trifiró; Gijsbertus Ziere; Bruno H Stricker
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

4.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

Authors:  K W Woodhouse; H A Wynne
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 5.  Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?

Authors:  H U Meier-Kriesche; B Kaplan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Exponentially increased risk of infectious death in older renal transplant recipients.

Authors:  H U Meier-Kriesche; A O Ojo; J A Hanson; B Kaplan
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

7.  CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.

Authors:  Dany Anglicheau; Eric Thervet; Isabelle Etienne; Bruno Hurault De Ligny; Yannick Le Meur; Guy Touchard; Matthias Büchler; Pierre Laurent-Puig; David Tregouet; Philippe Beaune; Ann Daly; Christophe Legendre; Pierre Marquet
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

8.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Authors:  Dennis A Hesselink; Ron H N van Schaik; Ilse P van der Heiden; Marloes van der Werf; Peter J H Smak Gregoor; Jan Lindemans; Willem Weimar; Teun van Gelder
Journal:  Clin Pharmacol Ther       Date:  2003-09       Impact factor: 6.875

9.  Galactose elimination capacity and liver volume in aging man.

Authors:  G Marchesini; V Bua; A Brunori; G Bianchi; P Pisi; A Fabbri; M Zoli; E Pisi
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

10.  Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney.

Authors:  Jill S Warrington; David J Greenblatt; Lisa L von Moltke
Journal:  J Pharmacol Exp Ther       Date:  2004-01-23       Impact factor: 4.030

View more
  34 in total

1.  Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Authors:  Rebecca A Pulk; David S Schladt; William S Oetting; Weihua Guan; Ajay K Israni; Arthur J Matas; Rory P Remmel; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2015-06-12       Impact factor: 2.533

Review 2.  Aging and the immune response to organ transplantation.

Authors:  Monica M Colvin; Candice A Smith; Stefan G Tullius; Daniel R Goldstein
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 3.  Kidney transplantation and the ageing immune system.

Authors:  Dianne McKay; Julie Jameson
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

4.  Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.

Authors:  W S Oetting; D P Schladt; W Guan; M B Miller; R P Remmel; C Dorr; K Sanghavi; R B Mannon; B Herrera; A J Matas; D R Salomon; P-Y Kwok; B J Keating; A K Israni; P A Jacobson
Journal:  Am J Transplant       Date:  2015-10-20       Impact factor: 8.086

5.  Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Authors:  T Vanhove; P Annaert; D Lambrechts; D R J Kuypers
Journal:  Pharmacogenomics J       Date:  2016-07-05       Impact factor: 3.550

Review 6.  Changes of T-cell Immunity Over a Lifetime.

Authors:  Yeqi Nian; Koichiro Minami; Ryoichi Maenesono; Jasper Iske; Jinrui Yang; Haruhito Azuma; Abdala ElKhal; Stefan G Tullius
Journal:  Transplantation       Date:  2019-11       Impact factor: 4.939

7.  Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Authors:  W S Oetting; B Wu; D P Schladt; W Guan; R P Remmel; R B Mannon; A J Matas; A K Israni; P A Jacobson
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

8.  The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.

Authors:  Jiang-Tao Tang; Brenda C de Winter; Dennis A Hesselink; Ferdi Sombogaard; Lan-Lan Wang; Teun van Gelder
Journal:  Br J Clin Pharmacol       Date:  2016-11-30       Impact factor: 4.335

9.  Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus.

Authors:  F Krenzien; M Quante; T Heinbokel; M Seyda; K Minami; H Uehara; H R C Biefer; J M Schuitenmaker; S Gabardi; K Splith; M Schmelzle; A K Petrides; H Azuma; J Pratschke; X C Li; A ElKhal; S G Tullius
Journal:  Am J Transplant       Date:  2016-11-21       Impact factor: 8.086

Review 10.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.